We recently presented updates from our Phase 2 KARDIA-2 and KARDIA-3 studies as part of our program to evaluate our investigational #RNAi therapeutic for the treatment of #hypertension at the 33rd European Meeting on Hypertension and Cardiovascular Protection #ESH2024. Learn more: https://bit.ly/4cn1Cg2
Alnylam Pharmaceuticals
Biotechnology Research
Cambridge, Massachusetts 193,741 followers
Alnylam is the leading RNAi therapeutics company. We're a fast-growing biopharma with a deep pipeline and global reach.
About us
To those who say “impossible, impractical, unrealistic,” we say: “CHALLENGE ACCEPTED.” Alnylam is the world's leading RNAi therapeutics company and the first and only company to bring RNAi-based medicines to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Alnylam is turning scientific possibility into reality - in 2018, the FDA and EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. We now have four additional medicines on the market. Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of 2,000+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we've been named a Science Magazine Top Employer 5 years in a row ('19-'23), a Boston Globe Top Place to Work 9x in a row ('15-'23) and Fast Company's #1 Best Workplace for Innovators ('22). We are based in Cambridge, U.S., with offices throughout Europe, Asia, and South America. See our community guidelines: https://bit.ly/2FcRhJy.
- Website
-
http://www.alnylam.com
External link for Alnylam Pharmaceuticals
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Public Company
- Founded
- 2002
- Specialties
- Biotech, Pharmaceuticals, Biopharma, Drug Development, Rare Diseases, and RNAi
Locations
Employees at Alnylam Pharmaceuticals
Updates
-
As a Massachusetts-based employer, we understand the critical importance of developing a robust, skilled workforce to support our #LifeSciences innovation ecosystem. We also understand that growing and sustaining that workforce requires collaboration, investment and attracting young people to careers in the life science. That's why we were thrilled to sponsor and participate in yesterday's MassBioEd Foundation 2024 Life Sciences Workforce Conference. This important gathering featured leaders from industry, community organizations, academic institutions, policy makers and more. Our CEO Dr. Yvonne Greenstreet and other members of our team took the stage to discuss ways that our state can build a strong and diverse life sciences workforce for the long game while navigating the expansion and contraction of the sector. #lswc24 #biotech #biopharma #WorkforceDevelopment
-
-
Congratulations to the members of the Alnylam Silencers/Heller's Angels who had a 🏀 at last Friday's Bio-Ball basketball tournament and are headed to the finals at TD Garden in December! Since 2007, Alnylam has proudly participated in #BioBall, which, with the Greater Boston #biotech community, raises critical funds for Special Olympics Massachusetts. This year, Alnylam's internal fundraising effort helped the tournament raise over $426,000! Bio-Ball fosters the spirit of inclusion through sports and the annual tournament helps support 14,000+ #SpecialOlympics athletes with intellectual disabilities. It's an incredible way for our biotech community to give back with impact. #ChooseToInclude
-
-
With beautiful weather, a huge group of Alnylam colleagues and family members and an incredible float produced by our SAGA - Sexuality & Gender Alliance employee resource network, last weekend’s #BostonPride parade was an unforgettable celebration of #pride 🌈. #DiverseEqualProud
-
#AlnylamScienceSpotlight: Among the many compelling potential applications of RNA interference (RNAi) technology, #obesity stands out as one we believe could be particularly well suited for #RNAi therapeutics - not only to deliver clinical benefit, but to have differentiating characteristics among the fast growing field of weight-loss medicines. That's why we're exploring novel gene targets, including GPR75 (with Regeneron) and INHBE, for potential drug candidates, the latter of which was initially identified as being linked to lower waist-to-hip ratio by Alnylam scientists in 2022. As the pioneer and leader in #RNAiTherapeutics, we're driven to advance the science of RNAi so as many people as possible can benefit from this innovative approach to #GeneSilencing. We're excited to see the effort and innovation biopharma is bringing forward to address the global obesity crisis, and are proud to be leading the way in exploring the important role RNAi may be able to play. Read the STAT News article here: https://bit.ly/4aSlTJd #RNAiRevolution #siRNA
-
-
Alnylam Pharmaceuticals reposted this
I spent an energizing afternoon in our UK office this week, connecting with our amazingly talented and diverse team. I loved hearing what inspires them about their work for patients and discussing the exciting future ahead of us at Alnylam Pharmaceuticals. The UK has long been a leader in the life sciences and has contributed to so many breakthroughs that continue to drive biopharmaceutical innovation. It’s always special for me to return to the country where I spent so much of my life and my career. Thank you to Philip Davey and the whole Alnylam team for your warm welcome! I can’t wait to come back. #RNAiRevolution #RNAiRevolutionary #RNAiTherapeutics
-
-
Understanding your family’s health history is vital. On the Family Health History Road Trip, learn about the importance of sparking conversations with your family and doctor to understand your risk of developing an inherited disease like #hATTR #amyloidosis. Follow along the journey and learn more about hATTR amyloidosis at https://bit.ly/3QPohJd. For medical advice, please consult a doctor. #hATTRoadTrip
This content isn’t available here
Access this content and more in the LinkedIn app
-
We shared new results from a post hoc subgroup analysis of the ENVISION Phase 3 study evaluating long-term impact of our #RNAi therapeutic for the treatment of acute hepatic #porphyria (AHP). Learn more: https://bit.ly/3VbRK1q #EASLCongress EASL | The Home of Hepatology
-
-
US Healthcare Professionals: Explore RNAiScience, a website that provides educational, clinical, and scientific information about Alnylam’s therapeutic areas and the science of RNA interference (RNAi). https://bit.ly/45a6Rgq #RNAi #RNAiTherapeutics #siRNA
-
-
Through the Alnylam Assist® program, patients have access to Alnylam Patient Education Liaisons (PELs), professionals who are experienced in providing disease and product education to patients and their family members. https://bit.ly/3URXbSy
Similar pages
Browse jobs
Stock
ALNY
NASDAQ
20 minutes delay
$160.39
0.34 (0.212%)
- Open
- 160.31
- Low
- 159.59
- High
- 163.02
Data from Refinitiv
See more info on